Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension


Cite item

Full Text

Abstract

The paper reviews current views of the problem of pulmonary hypertension. It shows the classification of pulmonary hypertension and considers the general issues of its pathogenesis, morphological changes, clinical picture, and main approaches to treating patients with pathology. Particular emphasis is placed on the review of clinical trials of the class of endothelin receptor antagonists.

Full Text

Роль антагониста эндотелиновых рецепторов бозентана в лечении больных легочной артериальной гипертензией. - Аннотация. В статье приводится обзор современных взглядов на проблему легочной гипертензии. Представлена классификация легочной гипертензии, рассматриваются общие вопросы патогенеза, морфологических изменений, клинической картины, диагностики, а также основных подходов к лечению больных с данной патологией. Особое внимание отводится обзору клинических исследований, посвященных классу антагонистов эндотелиновых рецепторов.
×

About the authors

N A Tsareva

Email: n_tsareva@mail.ru

References

  1. Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
  2. Gaine Sean P., Lewis J. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
  3. Vachiery J.-.L, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rew 2012; 21: 313-320.
  4. Chemla D., Castelain V., Hervé P. et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20 (5): 1314-1331.
  5. Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
  6. Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S56.
  7. Berger R.M., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537-546.
  8. Trulock E., Edwards L., Taylor D. et al. The registry of the International Society for Heart and Lung Transplantation: Twentieth Official Adult Lung and Heart-lung Transplant Report-2003. J Heart Lung Transplant 2003; 22: 625.
  9. Sitbon O., Morrell N.W. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012; 21 (126): 321-327.
  10. Denton C.P., Cailes J.B., Phillips G.D. et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36: 239-243.
  11. Guazzi M., Galie N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012; 21 (126): 338-346.
  12. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828-835.
  13. Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.
  14. Galie N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010; 31: 2080-2086.
  15. Resta T.C., Gonzales R.J., Dail W.G. et al. Selective uprequlation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 1997; 272: H806-H813.
  16. D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
  17. Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S56.
  18. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
  19. Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
  20. Galie N., Hoeper M., Torbicki A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
  21. Rich S., Rubin L.L., Abenhaim L. et al. Executive summary from the World Symposium on primary Pulmonary hypertension (Evian, France, September 6-10, 1998). Geneva: WHO 1998.
  22. Brij S., Peacock A.J. Pulmonary hypertension: its assessment and treatment. Thorax 1999; 54 (suppl. 2): S28-S32.
  23. D'Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur Respir Rev 2012; 21 (126): 328-337.
  24. Sitbon O., Badesch D., Channick R. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-254.
  25. Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-1123.
  26. Guyatt G.H., Sullivan M.J., Thompson P.J. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: 919-923.
  27. Rubin L.J. Primary pulmonary hypertension. Chest 1993; 104 (1): 236-250.
  28. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1999; 431: 111-119.
  29. Gossage J.R., Christman B.W. Mediators of acute and chronic pulmonary hypertension. Semin Respir. Crit Care Med 1994; 15: 453- 462.
  30. Galie N., Rubin L., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371: 2093-2100.
  31. Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты годичного исследования. Тер арх 2013; 3: 38-43.
  32. Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
  33. Berman E.B., Barst R.J. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002; 45: 129-138.
  34. Meyrick B. The pathology of pulmonary artery hypertension. Clin Chest Med 2001; 22: 393.
  35. Berman E.B., Barst R.J. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002; 45: 129-138.
  36. Galie N., Manes A., Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227-237.
  37. Giaid A., Yanagisawa M., Langleben D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
  38. Vongpatanasin W., Brickner M.E., Hillis L.D., Lange R.A. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128: 745-755.
  39. Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension: a national prospective study. Ann Intel'll Med 1987; 107: 216-223.
  40. Kuhr F.K., Smith K.A., Song M.Y. et al. New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling. Am J Physiol Heart Circ Physiol 2012; 302: H1546-1562.
  41. McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2229.
  42. Galie N., Rubin L.J., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371: 2093-2100.
  43. Savarese G., Paolillo S., Costanzo P. et al. Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension? A Meta-Analysis of 22 Randomized Trials. JACC 2012; 60 (13): 1192-1201.
  44. McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
  45. Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538-546.
  46. López-Candales A., Dohi K., Rajagopalan N. et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc Ultrasound 2005; 3: 23-32.
  47. Humbert M., Souza R., Galie N. et al. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev 2012; 21 (126): 267-270.
  48. Galie N., Rubin L.J. Pulmonary Arterial Hypertension: epidemiology, pathobiology, assessment, and therapy. J Am Coll Cardiol 2004; 12: 5S - 12S.
  49. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197.
  50. Jones R., Reid L. In Pulmonary Vascular Remodelling (eds Bishop J.E., Reeves J.T., Laurent G.J.). London: Portland Press Ltd. 1995; 47-116.
  51. Tuber R.M., Cool C.D., Yeager M. et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-418.
  52. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007; 28: 117-125.
  53. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001; 22: 433-449.
  54. Мартынюк Т.В., Архипова О.А., Кобаль Е.А. и др. Применение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гипертензией: первый российский опыт и взгляд в будущее. Системные гипертензии 2011; 4: 51-56.
  55. Sitbon O., Badesch D.B., Channick R.N. Effects of the dual endothelin-1 receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-254.
  56. Resta T.C., Gonzales R.J., Dail W.G. et al. Selective uprequlation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol 1997; 272: H806-H813.
  57. Fishman A.P., McGoon M.D., Chazova I.E. et al. Diagnosis and assessment of pulmonary hypertension. In: Rich S., ed. Primary pulmonary hypertension: executive summary from the world 1998. Accessed March 4, 2002.
  58. Deanfield J., Thaulow E., Warnes C. et al. Management of grown up congenital heart disease. Eur Heart J 2003; 24: 1035-1084.
  59. Чазова И.Е., Жданов В.С., Веселова С.П., Мареев В.Ю. Патология первичной легочной гипертензии. Арх патол 1993; 3: 52-55.
  60. Pietra G.G., Capion F., Stewart S. et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 25S-32S.
  61. McGoon M.D. The assessment of pulmonary hypertension. Clin Chest Med 2001; 22: 493.
  62. Cheever K. An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and management. J Cardiovasc Nurs 2005; 20: 108-116.
  63. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25: 2243-2278.
  64. Raymond R.J., Hinderliter A.L., Willis P.W. et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.
  65. Galie N., Manes A., Negro L. et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 2493-2537.
  66. O'Callaghan D.S., Savale L., Montani D. http://www.ncbi.nlm.nih.gov/pubmed?term=Ja%C3%AFs%20X%5BAuthor%5D&cauthor=true&cauthor_uid=21769113 et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011; 8 (9): 526-538.
  67. Voelkel N.F., Tuder R.M. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
  68. Dimopoulos K., Inuzuka R., Goletto S. et al. Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension. Circulation 2010; 1 (121): 20-25.
  69. Oya H., Nagaya N., Uematsu M. et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 2002; 143: 739-744.
  70. López-Candales A., Dohi K., Rajagopalan N. et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc Ultrasound 2005; 3: 23-32.
  71. Deanfield J., Thaulow E., Warnes C. et al. Management of grown up congenital heart disease. Eur Heart J 2003; 24: 1035-1084.
  72. Naeije R., Rondelet B. Pathobiology of pulmonary arterial hypertension. Bull Mem Acad R Med Belg 2004; 159 (Pt 2): 219-226.
  73. Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005; 112: 828 - 835.
  74. Morell N.W., Adnot S., Archer S.L. et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-31.
  75. Simonneau G., Galie N., Hoeper M.M. et al. An interim analysis of long-term outcome in patients treated with bosentan in the double-blind or open-label extension of the EARLY trial. Am J Respir Crit Care Med 2011; 183: A5886.
  76. Cacoub P., Dorent R., Maistre G. et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 1993; 71: 448-450.
  77. Мухарлямов Н.М. Легочное сердце. М: Медицина 1973; 264.
  78. Provencher S. Long-term Outcome with First-line Bosentan Therapy in Idiopathic Pulmonary Arterial Hypertension. Eur Heart J 2006; 27: 589-595.
  79. Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl 12): 40S-47S.
  80. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
  81. Vachiery J.-L., Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21 (126): 313-320.
  82. Voelkel N.F., Tuder R.M. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
  83. Humbert M., Coghlan J., Khanna D. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012; 21 (126): 306-312.
  84. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
  85. Galie N., Hinderliter A.L., Torbicki A. et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-1386.
  86. Gruenig N. Combination treatment of pulmonary arterial hypertension with bosentan and sildenafil. Clin Pharmacol 2009; 49: 1343-1352.
  87. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
  88. Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension: a national prospective study. Ann Intel'll Med 1987; 107: 216-223.
  89. Rubens C., Ewert R., Halank M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569.
  90. Roman A., Gispert P., Monfort V. et al. Long-term outcomes of treatment with bosentan in pulmonary hypertension. Arch Bronconeumol 2006; 42: 616-620.
  91. Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58: 538-546.
  92. Tanowitz H., Huang H., Jelicks L. et al. Role of endotelin 1 in the pathogenesis of chronic chagasic heart disease. Infect Immun 2005; 73: 2496-2503.
  93. ATS. ATS statement: guidelines for the 6-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
  94. Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies